In September 2017, I had the opportunity to renew my collaboration with the International Bar Association Healthcare and Life Sciences Committee, writing an article about falsified medicines in the European legal framework, which has been published as part of the Committee Newsletter, in view of the International Bar Association 2017 Annual Conference, which will take place in Sidney (8-13 October 2017).

The newsletter is accessible only to Committee members, so I am not authorized to share the entire article. Here its synopsis:

Production and trafficking in falsified medicines can be considered a real threat, sufficiently serious to undermine safety protocols’ ability to protect consumers’ health. The continuous expansion of darknet markets and unauthorized online websites represents an additional, valuable resource for traffickers, who exploit legislation grey areas to implement the business and go unpunished.”

If you want to join this Committee, please follow this link: ibanet.org/…care_Lifescience/Default.aspx